A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
← catalyst calendarSponsored by Erasca, Inc. (industry) · ERAS — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
101actual
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-20 | actual | When the study began enrolling |
| Primary completion | 2025-08-15 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-26 | actual | The whole study's end, after follow-up |
| First posted | 2021-09-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metastatic Colorectal Cancer
- Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
- Drug: ERAS-007
- Drug: Encorafenib — also filed as Braftovi
- Drug: Cetuximab — also filed as Erbitux
- Drug: Palbociclib — also filed as Ibrance
Primary outcomes
what the primary-completion date above is the date OFDose Limiting Toxicities (DLT)
measured Study Day 1 up to Day 29
Maximum Tolerated Dose (MTD)
measured Study Day 1 up to Day 29
Recommended Dose (RD)
measured Study Day 1 up to Day 29
Adverse Events
measured Assessed up to 24 months from time of first dose
Permalink · ERAS's whole pipeline · Catalyst calendar · Every registered study · What changed